HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Sms Pharmaceuticals Ltd Stock Comparison

Alivus Life Sciences Ltd vs Sms Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jun 29, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1001 as of 27 Jun 15:30.
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of SMS Pharmaceuticals Ltd changed from 7.1 on March 2020 to 30.2 on March 2024 . This represents a CAGR of 33.58% over 5 years.
  • The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of SMS Pharmaceuticals Ltd changed from ₹ 225.6 crore on March 2020 to ₹ 1507 crore on March 2024 . This represents a CAGR of 46.21% over 5 years.
  • The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of SMS Pharmaceuticals Ltd for the Mar '25 is ₹ 249.62 crore as compare to the Dec '24 revenue of ₹ 175.48 crore. This represent the growth of 42.25%.
  • The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of SMS Pharmaceuticals Ltd for the Mar '25 is ₹ 42.23 crore as compare to the Dec '24 ebitda of ₹ 35.34 crore. This represent the growth of 19.5%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of SMS Pharmaceuticals Ltd changed from ₹ 8.81 crore to ₹ 20.08 crore over 8 quarters. This represents a CAGR of 50.97% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 58.56 % on March 2024 . This represents a CAGR of -1.60% over 3 yearsThe Dividend Payout of SMS Pharmaceuticals Ltd changed from 6.48 % on March 2020 to 6.86 % on March 2024 . This represents a CAGR of 1.15% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018.
  • A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited.
  • The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

About SMS Pharmaceuticals Ltd

  • SMS Pharmaceuticals Limited was incorporated in December, 1987.
  • The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates.
  • Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa Village in Vijayanagaram District of Andhra Pradesh.
  • Its business activity is a single primary business segment of 'Bulk Drugs'. During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities. During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24. During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs.

Alivus Life Sciences Ltd News Hub

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

News

Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking a...

Read more

20 Jan 2025 10:18

SMS Pharmaceuticals Ltd News Hub

News

SMS Pharma's Hyderabad facility clears USFDA inspection with zero observations

The inspection was conducted from 23rd June 2025 to 25th June 2025, concluded with zero Fo...

Read more

26 Jun 2025 08:27

News

Board of SMS Pharmaceuticals recommends final dividend

SMS Pharmaceuticals announced that the Board of Directors of the Company at its meeting he...

Read more

31 May 2025 14:45

News

SMS Pharmaceuticals to announce Quarterly Result

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 May...

Read more

24 May 2025 18:31

News

SMS Pharmaceuticals' Unit VII receives WHO Geneva prequalification

SMS Pharmaceuticals announced that Unit VII manufacturing facility in Visakhapatnam, Andhr...

Read more

02 May 2025 12:36

News

SMS Pharma gains after Hyderabad facility completes USFDA inspection

According to an exchange filing, the inspection was conducted from 17 March to 21 March 20...

Read more

24 Mar 2025 09:59

News

SMS Pharma's Hyderabad facility completes USFDA inspection with 1 observation

According to an exchange filing, the inspection was conducted from 17 March to 21 March 20...

Read more

22 Mar 2025 16:28

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

SWOT Analysis Of SMS Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

2

T

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for SMS Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and SMS Pharmaceuticals Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or SMS Pharmaceuticals Ltd?

Market cap of Alivus Life Sciences Ltd is 12,278 Cr while Market cap of SMS Pharmaceuticals Ltd is 2,203 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and SMS Pharmaceuticals Ltd?

The stock performance of Alivus Life Sciences Ltd and SMS Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and SMS Pharmaceuticals Ltd?

As of June 29, 2025, the Alivus Life Sciences Ltd stock price is INR ₹1001.25. On the other hand, SMS Pharmaceuticals Ltd stock price is INR ₹248.6.

How do dividend payouts of Alivus Life Sciences Ltd and SMS Pharmaceuticals Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and SMS Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions